GL1X · GenesisL1 explorer

MolNFT v1 · #181502 · protein

Uk (B.1.1.7) SARS-cov-2 spike protein variant (S-gsas-B.1.1.7) in the 1-rbd-up conformation

7LWT · Spike glycoprotein: “Uk (B.1.1.7) SARS-cov-2 spike protein variant (S-gsas-B.1.1.7) in the 1-rbd-up conformation”. Electron microscopy, 1 ligand (NAG), 20 pockets (best druggability 0.86). MolNFT v1 #181502 on GenesisL1: 3D…

PDB
7LWT
Type
protein
Length
2,980 residues
Chains
3
Method
electron microscopy
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Spike glycoprotein
UniProt
P0DTC2
Ligands
NAG
Pockets
20 · best druggability 0.86

Structure

electron microscopy · 3 distinct chains · 23% helix, 33% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ASpike glycoproteinprotein99324% helix, 34% strandP0DTC2
BSpike glycoproteinprotein99523% helix, 32% strandP0DTC2
CSpike glycoproteinprotein99223% helix, 33% strandP0DTC2

Ligands and binding sites

  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · sugar · 48 copies · chains A, B, C

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

20 pockets found on a 1 Å grid, 20 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
110230.860.87105empty
25550.840.8964empty
38380.810.8494empty
47050.790.8480empty
57440.760.8155empty

Interfaces

3 interfaces between chains.

  • A–B · 5040 Ų buried · 49 hydrogen bonds · protein-protein
  • A–C · 4910 Ų buried · 44 hydrogen bonds · protein-protein
  • B–C · 4440 Ų buried · 41 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 39 glycan, 38 disulfide (N-glycosylation, disulfide).

Compared structures

  • 7LWT · UK (B.1.1.7) SARS-CoV-2 spike protein variant (S-GSAS-B.1.1.7) in the 1-RBD-up… · the same entry in another collection · chain C against C, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.